Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m(2) intravenously (days 1, 8, 15), every 4 weeks in patients with previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil-Delgado, Maria Angeles, Lucidarme, Olivier, Bachet, Jean Baptiste, Mahi, Naima, Khayat, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167727/
https://www.ncbi.nlm.nih.gov/pubmed/30283289
http://dx.doi.org/10.1159/000490906
_version_ 1783360249026052096
author Gil-Delgado, Maria Angeles
Lucidarme, Olivier
Bachet, Jean Baptiste
Mahi, Naima
Khayat, David
author_facet Gil-Delgado, Maria Angeles
Lucidarme, Olivier
Bachet, Jean Baptiste
Mahi, Naima
Khayat, David
author_sort Gil-Delgado, Maria Angeles
collection PubMed
description We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m(2) intravenously (days 1, 8, 15), every 4 weeks in patients with previously treated advanced gastroesophageal junction adenocarcinoma. A 64-year-old man with gastroesophageal junction adenocarcinoma and liver metastases received first-line folinic acid, 5-fluorouracil plus oxaliplatin (FOLFOX) following jejunostomy. On liver progression, he enrolled in RAINBOW (April 2012), receiving ramucirumab. In November 2013, positron emission tomography scan was consistent with complete metabolic response, confirmed by a follow-up scan in March 2016.
format Online
Article
Text
id pubmed-6167727
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-61677272018-10-03 Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab Gil-Delgado, Maria Angeles Lucidarme, Olivier Bachet, Jean Baptiste Mahi, Naima Khayat, David Case Rep Gastroenterol Single Case We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m(2) intravenously (days 1, 8, 15), every 4 weeks in patients with previously treated advanced gastroesophageal junction adenocarcinoma. A 64-year-old man with gastroesophageal junction adenocarcinoma and liver metastases received first-line folinic acid, 5-fluorouracil plus oxaliplatin (FOLFOX) following jejunostomy. On liver progression, he enrolled in RAINBOW (April 2012), receiving ramucirumab. In November 2013, positron emission tomography scan was consistent with complete metabolic response, confirmed by a follow-up scan in March 2016. S. Karger AG 2018-08-31 /pmc/articles/PMC6167727/ /pubmed/30283289 http://dx.doi.org/10.1159/000490906 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Gil-Delgado, Maria Angeles
Lucidarme, Olivier
Bachet, Jean Baptiste
Mahi, Naima
Khayat, David
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_full Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_fullStr Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_full_unstemmed Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_short Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
title_sort long-term survival in gastroesophageal junction adenocarcinoma: ramucirumab
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167727/
https://www.ncbi.nlm.nih.gov/pubmed/30283289
http://dx.doi.org/10.1159/000490906
work_keys_str_mv AT gildelgadomariaangeles longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab
AT lucidarmeolivier longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab
AT bachetjeanbaptiste longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab
AT mahinaima longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab
AT khayatdavid longtermsurvivalingastroesophagealjunctionadenocarcinomaramucirumab

Ejemplares similares